That brings Haley's holdings to $1,130,657 per an SEC filing yesterday. In terms of relative volume, these shares are trading at 2.04x their normal volume.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. This recommendation lands on a scale between 1 and 5. That brings the President and CEO's holdings to $1,614,000 as recorded in a recent Form 4 SEC filing.
Fmr LLC grew its position in Exelixis, Inc. During last 3 month period, -1.09% of total institutional ownership has changed in the company shares. Meditor Group Ltd increased its stake in Exelixis by 5.5% in the 2nd quarter. The firm owned 317,426 shares of the biotechnology company's stock after selling 529,730 shares during the period. When volumes suddenly increase above normal levels, it can be a sign that investors feel very strongly in one way or the other about the future direction of a stock, or may even have access to inside information.
In recent action, Exelixis, Inc.
Insider Trades for Exelixis, Inc. show that the latest trade was made on 13 Sep 2017 where Morrissey (Michael M), the Chief Executive Officer completed a transaction type "Sell" in which 100000 shares were traded at a price of $27.08. The YTD performance of the stock stands at 84.91 Percent. Exelixis has $34.0 highest and $15 lowest target. The firm has a market capitalization of $7.19 billion, a PE ratio of 123.59 and a beta of 1.97. The stock's 50 day moving average price is $27.06 and its 200 day moving average price is $23.39.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. The business had revenue of $99.01 million for the quarter, compared to analysts' expectations of $85.27 million. Comparatively, the peers have a net margin 16.73%, and the sector's average is 53.71%. The firm's revenue was up 173.1% on a year-over-year basis. Next quarter's EPS is estimated at $0.08 with next year's EPS anticipated to be $0.66. (NASDAQ:EXEL) recently. Director Stelios Papadopoulos sold 200,000 shares at a price of $27.70 on September 19th. The shares sold for $27.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The shares were sold at an average price of $25.40, for a total value of $254,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 560,640 shares of company stock valued at $15,087,014.
Looking into last 5 trades, the stock observed a return of nearly 2.83%. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.
On September 22 the company was set at "Market Perform" in a report from Leerink Swann which was a cut from the previous "Outperform" rating. Oppenheimer maintained the shares of EXEL in report on Thursday, July 20 with "Hold" rating. The company presently has an average rating of "Buy" and a consensus price target of $26.51. Oppenheimer Holdings, Inc. reissued a "hold" rating on shares of Exelixis in a research note on Sunday, September 10th. Analysts giving shares a rating of 1 or 2 would be indicating a Buy. As per Thursday, November 3, the company rating was initiated by Deutsche Bank. Seven analysts have rated the stock with a buy rating, The company has a consensus rating of "Buy" and an average target price of $15.60.
08/02/2017 - Exelixis, Inc. had its "outperform" rating reiterated by analysts at Cowen.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & global trademark and copyright laws. Wetherby Asset Management Inc. acquired a new position in Exelixis during the second quarter worth about $218,000. The Firm is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer.